Posted by Michael Wonder on 01 Sep 2024
Cabometyx (cabozantinib) now available for eligible patients with non-clear cell renal cell carcinoma via the PBS
1 September 2024 - Cabometyx (cabozantinib), a once daily oral medication, is now available on the PBS for eligible patients with stage IV non-clear cell renal cell carcinoma.
Previously, patients living with stage IV non-clear cell renal cell carcinoma had no PBS reimbursed treatment option.
